What the Lawsuits Allege
Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist made by Novo Nordisk, used for type 2 diabetes and widely for weight loss. The litigation also touches related drugs in the same class. Plaintiffs allege two main groups of injuries. The larger group alleges severe gastrointestinal harm, especially gastroparesis, or stomach paralysis, along with intestinal blockage and related conditions. A second, newer group alleges sudden vision loss from a condition known as NAION.
The core legal theory is failure to warn, that the manufacturer did not adequately disclose these risks on the label. Novo Nordisk maintains that its GLP-1 medications are safe and is defending against the allegations, and causation is heavily contested, in part because some of the conditions can have other causes.
Two Separate MDLs
The federal cases are organized into two multidistrict litigations, both in the Eastern District of Pennsylvania before Judge Karen Marston. The first, MDL 3094, covers the gastrointestinal injuries and holds thousands of cases. The second, MDL 3163, was created in December 2025 specifically for the NAION vision-loss claims, which were distinct enough from the stomach injuries to warrant their own proceeding. Related state-court litigation also exists.
Both are multidistrict litigations, not class actions, so each plaintiff keeps an individual case. The litigation is still in earlier stages, with discovery and the groundwork for evaluating the scientific evidence underway.
Where Things Stand
No bellwether trials have taken place in either MDL, and no settlement has been reached. A central battleground will be causation, whether the evidence reliably shows the drugs can cause the claimed injuries, which the courts will test before any trials proceed. The gastrointestinal litigation is further along than the newer vision-loss proceeding.
Eligibility generally centers on having taken Ozempic or a related GLP-1 drug and suffered a qualifying injury, with medical documentation, including for those whose symptoms resolved after stopping the drug. Because the litigation is developing and deadlines vary by state, there is no reliable individual figure yet, and a prompt assessment is the practical step.
How to Get Legal Help
If you or a family member fits the description here, a consultation with a lawyer who handles this specific litigation is the reliable next step. Deadlines vary by state and can be unforgiving, most of these firms offer a free review, and these cases are typically taken on contingency, so you pay nothing unless they recover for you.
To follow filings, trial outcomes, and any settlement news, bookmark this page and subscribe to LawsuitWatch alerts.
Free Legal Evaluation
Do You Qualify to File a Claim?
Our network of verified plaintiff attorneys offers free, no-obligation case evaluations. Contingency fee representation means you pay nothing unless you win.
Ozempic Lawsuit: The Stomach and Vision Claims Explained: Frequently Asked Questions
Answers to the most common questions about this case and your legal options.
What do Ozempic lawsuits allege?
Two main groups of injuries: severe gastrointestinal harm, especially gastroparesis or stomach paralysis, and separately sudden vision loss from a condition called NAION, all under a failure-to-warn theory. Novo Nordisk maintains its GLP-1 drugs are safe and contests the claims.
Is there one Ozempic MDL or two?
Two, both in the Eastern District of Pennsylvania before Judge Karen Marston. MDL 3094 covers the gastrointestinal injuries, and MDL 3163, created in December 2025, covers the NAION vision-loss claims. Both are MDLs, not class actions.
What is gastroparesis?
Gastroparesis, sometimes called stomach paralysis, is a condition in which the stomach empties too slowly, causing severe nausea, vomiting, and other problems. It is the most common injury alleged in the gastrointestinal MDL.
Have there been any trials or settlements?
No. No bellwether trials have taken place in either MDL and no settlement has been reached. Causation, whether the drugs can reliably be shown to cause the injuries, will be a central issue tested before trials.
Who may qualify?
Generally someone who took Ozempic or a related GLP-1 drug and developed a qualifying injury with medical documentation, including people whose symptoms resolved after stopping. Deadlines vary by state, so a prompt assessment matters.